Fluidx Completes Follow-Up in Multicenter Study of GPX Liquid Embolic Agent

October 6, 2022—Fluidx Medical announced the completion of follow-up in its multicenter clinical trial examining the broad application of the company’s new GPX liquid embolic agent for arterial and venous embolization. On September 1, the company announced that the final patient was enrolled in the study, which was conducted at sites in New Zealand.

Study investigator Martin Krauss, MD, Head of Interventional Radiology at Christchurch Hospital in Christchurch, New Zealand, commented in the company’s press release, “In the study, GPX was successfully used to treat a range of hypervascular tumors as well as other arterial and venous applications. The embolic flowed nicely, providing excellent control and beautiful filling of distal branches.”

The trial’s Principal Investigator is Andrew Holden, MBChB, who is Director of Interventional Radiology at Auckland City Hospital in Auckland, New Zealand.

Fluidx reported that the study investigators have achieved 30-day follow-up in all patients, with some patients now at more than 1 year from their procedures and doing well. The company expects that these findings will be published. Interim results of the GPX study have been presented at recent annual congresses including Global Embolization Symposium & Technologies, Society of Interventional Radiology, and Leipzig Interventional Course.

According to the company, GPX addresses a common concern of liquid embolics that the delivery microcatheter tip may become entrapped in solidifying embolic following deployment. The GPX material does not entrap existing delivery microcatheters, and no entrapment was observed during the study. Freedom from this concern allowed clinicians to take time during material delivery to ensure complete occlusion of the targeted region.

Fluidx Medical stated that GPX technology is a low viscosity, aqueous-based solution that solidifies into a durable embolus upon delivery without polymerization or dimethyl-sulfoxide precipitation. The platform is expected to provide simple preparation and controllable material delivery to several embolic applications.

The GPX embolic device is under development and does not have marketing clearance or approval in any market at this time, advised Fluidx Medical.